메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

TraceLink Customers Demonstrate Readiness as DSCSA Dispenser Deadline Arrives

TraceLink Continues to Set the Standard for United States Drug Supply Chain Security (DSCSA) Leadership, Proven by Real-World Success, Industry Adoption, and Superior Service BOSTON, Nov. 10, 2025 -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the pharmaceutical supply chain, continues to set the standard for Drug Supply Chain Security Act (DSCSA) readiness as the dispenser compliance deadline approaches on November 27, 2025. This milestone marks the culmination of a decade-long, multi-phase industry effort to secure the U.S. phar
- 김갑성 기자
- 2025-11-10 23:00
자말 엘타에브 박사, '2025 오로라 인류 각성상' 수상자로 선정

엘타에브 박사는 수단 알나오 병원장으로서, 내전 속에서도 중환자 치료를 지속하며 수백 명의 생명을 구한 공로를 인정받아 뉴욕, 2025년 11월 10일 -- 전 세계의 가장 취약한 이들을 돕기 위해 설립된 비영리 재단인 오로라 인도주의 이니셔티브(Aurora Humanitarian Initiative, 이하 '오로라')가 목요일 저녁 자말 엘타에브(Jamal Eltaeb) 박사가 '2025년 오로라 인류 각성상(Aurora Prize for Awakening Humanity)' 수상자로 선정돼 100만 달러를 지원받게 됐다고 발표했다. 이 상은 타인을 구하기 위해 목숨을 걸고 헌신하는 개인을 기리는 상이다. 올해 오로라는 분쟁에 휘말린 이들에게 의료 지원을 제공하기 위해 비범한 용기와 흔들림 없는 헌신을 보여준 공로를 인정해 엘타에브 박사를 수상자로 선정했다. 수단에서 참혹한 내전이 이어지며 국가 의료 시스템이 사실상 완전히 붕괴된 상황에서도 엘타에브 박사는 중부 옴두르만에 있는 알나오 병원(Al Nao Hospital)을 수도 하르툼 광역권에서 마지막으로 기능하는 전원병원(referral hospi
- 김갑성 기자
- 2025-11-10 22:00
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B

Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-179 anti-HBs responders showing faster and greater HBsAg reduction DURHAM, N.C. and BEIJING, Nov. 10, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and cho
- 김갑성 기자
- 2025-11-10 21:30
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - LEHI, Utah, Nov. 10, 2025 -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the
- 김갑성 기자
- 2025-11-10 21:15
Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"

70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company dedicated to developing novel therapies for rare and intractable diseases, today shared the interim Phase II clinical data for its "first-in-class" Tosposertib (TU2218), a dual inhibitor against TGFβ type I receptor (TGFβRI /ALK5) and VEGFR2. The study eva
- 김갑성 기자
- 2025-11-10 21:00
Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo

BOSTON, Nov. 10, 2025 -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-Generation Sequencing (NGS) library preparation. By integrating AI-driven design and high-throughput assays, Fapon actively leverages its AI-enabled enzyme engineering platform to improve product performance. Its showcased enzymes and reagents are engineered to enhance the accuracy, efficiency, and rel
- 김갑성 기자
- 2025-11-10 20:30
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

NANJING, China, Nov. 10, 2025 -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of moderate-to-severe atopic dermatitis (AD). The first dose was achieved in Hangzhou First People's Hospital. This randomized, double-blind, placebo-controlled, multi-center Phase II study is aiming to evaluate the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration of SIM0278 in participants with moder
- 김갑성 기자
- 2025-11-10 20:06
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)

SEOUL, South Korea, Nov. 10, 2025 -- LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Cholangitis (PSC), a rare and progressive liver disease with no approved treatments on November 5 (local time in the U.S.). LB-P8: A First in Class Candidate Targeting the Gut-Liver axis PSC is a cholestatic liver disease of unknown etiology, characterized by inflammation and fibrosis of the bile d
- 김갑성 기자
- 2025-11-10 20:00
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

HONG KONG, Nov. 10, 2025 -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the company's first-in-class bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), for the adjuvant treatment of pancreatic cancer following surgical resection. AK154 is Akeso's first mRNA-based therapeutic candidate to enter clinical development. This achievement marks a significant breakth
- 김갑성 기자
- 2025-11-10 19:39
MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model

HONG KONG, Nov. 10, 2025 -- Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("MediTrust Health") signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation around innovative drugs and commercial insurance, jointly explore a new model of drug-insurance integration, and help more patients access high-quality, affordable medicines at an earlier stage. Mr. Tse Hsin, Executive Director an
- 김갑성 기자
- 2025-11-10 14:18

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분